Acting in the gut, these antibodies promote the induction of a specific subset of Tregs, CD4+/CD25-latency associated peptide (LAP)+ T-cells, which migrate to lymph nodes where they exert their immunosuppressive effects, finally leading to a decrease in the Th1-Th17/Treg ratio and to an improvement of NASH [89]. The gene discussed is CD4; the disease is metabolic dysfunction-associated steatohepatitis.